4T1 Cell Membrane Biomimetic Nanovehicle for Enhanced Breast Cancer Treatment.

IF 3.5 3区医学 Q2 CHEMISTRY, MEDICINAL ACS Medicinal Chemistry Letters Pub Date : 2024-12-16 eCollection Date: 2025-01-09 DOI:10.1021/acsmedchemlett.4c00425

Mengkang Liu, Yufeng Sun, Qiuxian Wei, Anna Zhang, SaiFei Wang, Dan Wang, Zhipeng Dong, Xiaonan Ma, Ran Yan, Yue Wang

{"title":"4T1 Cell Membrane Biomimetic Nanovehicle for Enhanced Breast Cancer Treatment.","authors":"Mengkang Liu, Yufeng Sun, Qiuxian Wei, Anna Zhang, SaiFei Wang, Dan Wang, Zhipeng Dong, Xiaonan Ma, Ran Yan, Yue Wang","doi":"10.1021/acsmedchemlett.4c00425","DOIUrl":null,"url":null,"abstract":"<p><p>In this study, hollow mesoporous silica nanoparticles (HMSN) coated with a 4T1 tumor cell membrane were used to construct biomimetic nanomaterials (DTX@CHMSN) for the treatment of breast cancer. The nanodrug can improve the water solubility of polyenetaxel (DTX) by taking advantage of the special structure, good biocompatibility, and adjustable surface chemical properties of HMSN. Hollow mesoporous silica nanoparticles are coated with 4T1 cell membranes derived from homologous tumors (CHMSN). Adhesion glycoproteins on cancer cell membranes specifically bind to receptors on the cell membranes of the same cancer cell to target specific breast cancer tissues. At the same time, the cell membrane of the 4T1 tumor also contains CD47 protein, which can be specifically recognized by the immune system to produce immune escape. Therefore, the biomimetic nanomedicine DTX@CHMSN, with homologous targeting and immune escape ability, can accumulate in large quantities at the tumor site, reduce systemic toxicity, and thus improve the therapeutic effect.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 1","pages":"51-58"},"PeriodicalIF":3.5000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726363/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsmedchemlett.4c00425","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/9 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

In this study, hollow mesoporous silica nanoparticles (HMSN) coated with a 4T1 tumor cell membrane were used to construct biomimetic nanomaterials (DTX@CHMSN) for the treatment of breast cancer. The nanodrug can improve the water solubility of polyenetaxel (DTX) by taking advantage of the special structure, good biocompatibility, and adjustable surface chemical properties of HMSN. Hollow mesoporous silica nanoparticles are coated with 4T1 cell membranes derived from homologous tumors (CHMSN). Adhesion glycoproteins on cancer cell membranes specifically bind to receptors on the cell membranes of the same cancer cell to target specific breast cancer tissues. At the same time, the cell membrane of the 4T1 tumor also contains CD47 protein, which can be specifically recognized by the immune system to produce immune escape. Therefore, the biomimetic nanomedicine DTX@CHMSN, with homologous targeting and immune escape ability, can accumulate in large quantities at the tumor site, reduce systemic toxicity, and thus improve the therapeutic effect.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

ACS Medicinal Chemistry Letters CHEMISTRY, MEDICINAL-

CiteScore

7.30

自引率

2.40%

发文量

328

审稿时长

1 months

期刊介绍： ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to: Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics) Biological characterization of new molecular entities in the context of drug discovery Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc. Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic Mechanistic drug metabolism and regulation of metabolic enzyme gene expression Chemistry patents relevant to the medicinal chemistry field.